ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ANIP ANI Pharmaceuticals Inc

61.44
0.62 (1.02%)
05 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
ANI Pharmaceuticals Inc NASDAQ:ANIP NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.62 1.02% 61.44 54.54 68.18 61.57 60.56 60.96 129,342 22:30:00

ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET

18/04/2024 9:05pm

GlobeNewswire Inc.


ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart


From Apr 2024 to Jul 2024

Click Here for more ANI Pharmaceuticals Charts.

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May 10, 2024, prior to the market open.

Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows:

DateFriday, May 10, 2024
  
Time8:30 a.m. ET
  
Toll free (U.S.)800-274-8461
  
Conference ID4555224
  
Webcast (live and replay)www.anipharmaceuticals.com, under the “Investors” section
  

A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-938-2239 and entering access code 4555224.

About ANI ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset Purified Cortrophin® Gel, strengthening its Generics business with enhanced research and development capabilities, leveraging its U.S. based manufacturing footprint, and delivering innovation in Established Brands. For more information, please visit our website www.anipharmaceuticals.com.

Investor Relations Contact:Lisa M. Wilson, In-Site Communications, Inc.212-452-2793lwilson@insitecony.com

SOURCE: ANI Pharmaceuticals, Inc.

1 Year ANI Pharmaceuticals Chart

1 Year ANI Pharmaceuticals Chart

1 Month ANI Pharmaceuticals Chart

1 Month ANI Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock